Illuminare Biotechnologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Illuminare Biotechnologies is pioneering a novel surgical aid focused on preventing iatrogenic nerve injury through real-time visualization. Its lead asset, Illuminare-1, has shown promising safety and initial efficacy in a Phase 1 trial at Memorial Sloan Kettering, with results published in JAMA Surgery. The company is a private, pre-revenue entity planning to advance into Phase 2 clinical development in 2026, targeting significant unmet needs in oncologic and other complex surgeries.

OncologyImmunology

Technology Platform

Proprietary small molecule platform for intra-operative nerve visualization, featuring immediate onset and sustained duration of illumination to differentiate nerves from surrounding tissue during surgery.

Opportunities

Addresses a massive unmet need in surgical oncology and beyond, where iatrogenic nerve injury is a common, costly complication.

Successful Phase 2 data could enable expansion into multiple high-volume surgical indications, creating a blockbuster surgical adjunct product.

The novel mechanism and clinical validation position the company as an attractive partner for larger medtech or pharma firms.

Risk Factors

High clinical development risk: Phase 2 may not confirm efficacy seen in early studies.

Unproven regulatory pathway for a surgical visualization agent and future reimbursement challenges.

Competition from alternative imaging technologies or surgical techniques.

Reliance on future financing rounds in a challenging biotech capital environment.

Competitive Landscape

The field of intra-operative nerve-specific visualization is nascent, with few direct competitors. Competition may arise from advanced imaging hardware (e.g., hyperspectral imaging, confocal microscopy) or alternative contrast agents (e.g., antibody-based fluorescent probes). Illuminare's primary competition is the current standard of care: surgeon experience and anatomical knowledge without targeted visualization aids.

More companies in Diagnostics & Precision Medicine →More companies in United States →